The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis
© Bergeron et al; licensee BioMed Central Ltd. 2010
Received: 30 April 2010
Accepted: 13 October 2010
Published: 13 October 2010
Among the most harmful of all genetic abnormalities that appear in colorectal cancer (CRC) development are mutations of KRAS and its downstream effector BRAF as they result in abnormal extracellular signal-related kinase (ERK) signaling. In a previous report, we had shown that expression of a constitutive active mutant of MEK1 (caMEK) in normal rat intestinal epithelial cells (IECs) induced morphological transformation associated with epithelial to mesenchymal transition, growth in soft agar, invasion and metastases in nude mice. Results from microarrays comparing control to caMEK-expressing IECs identified the gene encoding for serpinE2, a serine protease inhibitor, as a potential target of activated MEK1.
1- RT-PCR and western blot analyses confirmed the strong up-regulation of serpinE2 expression and secretion by IECs expressing oncogenic MEK, Ras or BRAF. 2- Interestingly, serpinE2 mRNA and protein were also markedly enhanced in human CRC cells exhibiting mutation in KRAS and BRAF. 3- RNAi directed against serpinE2 in caMEK-transformed rat IECs or in human CRC cell lines HCT116 and LoVo markedly decreased foci formation, anchorage-independent growth in soft agarose, cell migration and tumor formation in nude mice. 4- Treatment of CRC cell lines with U0126 markedly reduced serpinE2 mRNA levels, indicating that expression of serpinE2 is likely dependent of ERK activity. 5- Finally, Q-PCR analyses demonstrated that mRNA levels of serpinE2 were markedly increased in human adenomas in comparison to healthy adjacent tissues and in colorectal tumors, regardless of tumor stage and grade.
Our data indicate that serpinE2 is up-regulated by oncogenic activation of Ras, BRAF and MEK1 and contributes to pro-neoplastic actions of ERK signaling in intestinal epithelial cells. Hence, serpinE2 may be a potential therapeutic target for colorectal cancer treatment.
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in North America. Number of genetic and epigenetic alterations has been reported to be involved in colorectal tumorigenesis, such as chromosome instability, DNA methylation, gene amplification and mutation. APC is the most frequently mutated gene (53.8%), followed by TP53 (37.2%) and the two members of the MAPK pathway, KRAS (35.1%) and BRAF (10%) . In this regard, aberrant activation of the Ras/Raf/MEK/ERK pathway leads to the downstream activation of MEK1/2 and ERK1/2 kinases, which may control many features of tumorigenesis . In keeping with this observation, we and others have recently shown that expression of constitutively active MEK1 in non-transformed rodent intestinal epithelial crypt cell lines is sufficient to induce growth factor relaxation for DNA synthesis and to promote morphological transformation and growth in soft agar [3, 4]. Accordingly, it has been demonstrated that MEK is phosphorylated and activated in 30-40% of adenomas and in 76% of colorectal tumors [5, 6]. CRCs also exhibit particularly high frequencies of ERK activation  and some studies have reported that ERK1/2 activities are indeed elevated in intestinal tumors [8, 9]. Therefore, much emphasis has been placed on treatment strategies that target this protein kinase cascade . In particular, potent and selective inhibitors of MEK1 and MEK2 have been developed and have been tested in phase I/II clinical trials (AZD6244, XL51, and ARRY-162) [11, 12]. Interestingly, an early study reported that the enzymatic activity of ERK1/ERK2 is markedly up-regulated during late progression of carcinogen-induced colon carcinomas . In this respect, activation of MEK1 and MEK2 in intestinal epithelial cells is sufficient to induce invasive and metastatic tumors in nude mice [14, 15]. Together, these observations strengthen the notion that ERK1/2 MAP kinase signaling may play a critical role in CRC progression . However, in spite of the obvious role of MEK/ERK kinases in the induction and regulation of intestinal epithelial cell transformation, tumorigenesis and metastasis, little is known regarding the molecular mechanism by which MEK/ERK signaling achieves such functions.
In order to further understand the mechanisms by which activated MEK1 induces tumorigenesis in intestinal epithelial cells, we have analyzed by microarray the pattern of gene expression in intestinal epithelial (IEC-6) cells overexpressing activated MEK1. Importantly, Serpin clade E member 2 (SerpinE2), emerges as the highest up-regulated gene induced by activated MEK1. Serpins are SERine Protease INhibitors targeting proteases prostatin [17–19], matriptase , T cell proteinase-1 , trypsin, thrombin, plasmin and plasminogen activator [22, 23]. Through their ability to reduce proteolysis, serpins are predicted to impair extracellular matrix degradation and consequently cancer cell invasion and metastasis. However, serpinE1 (or plasminogen activator inhibitor-1, PAI-1) has been reported to promote angiogenesis and to induce tumor cell migration [24–26] while serpinE2 (or protease nexin-1, PN-1) appears to enhance the invasive potential of pancreatic , breast  and lung cancer cells . Furthermore, serpinE1 is overexpressed in highly aggressive human breast tumors while serpinE2 levels are elevated in pancreatic tumors , breast tumors , oral squamous carcinomas , liposarcomas  and more recently CRCs .
In the present study, we show that RNA interference (RNAi) targeting serpinE2 in MEK1-transformed rat IECs or in human colorectal cancer cells decreased anchorage independent growth, migration and tumor formation in nude mice. Furthermore, serpinE2 is overexpressed in human adenomas and colorectal tumors compared to the adjacent healthy tissues. Therefore, our results demonstrate an important role for serpinE2 in colorectal tumorigenesis.
SerpinE2 is overexpressed in intestinal epithelial cells transformed by activated MEK1 and oncogenic RAS and BRAF
Since serpinE2 protein is known to be secreted [22, 33], we easily confirmed its presence in conditioned culture medium of caMEK-expressing IECs whereas no serpinE2 protein was detected in the culture medium of wtMEK-expressing or parental IECs (Figure 1D). Again, treatment with the MEK-inhibitor U0126 completely abrogated serpinE2 secretion (Figure 1D). Interestingly, serpinE2 protein was difficult to detect in total cell lysates (Figure 1E, lane 2). However, serpinE2 was easily observed in lysates prepared from foci of post-confluent caMEK-expressing cells (Figure 1E, lane 4), while it was not detectable in the surrounding monolayer (Figure 1E, lane 3). This indicates a stronger expression of serpinE2 protein by the transformed IECs forming the foci.
Gene silencing of serpinE2 decreases foci formation, growth in soft agarose and migration induced by activated MEK
To determine the functional role of serpinE2 in caMEK-expressing cells, the proliferation rate of these cell populations was assessed when cultured on plastic. No difference was observed in the proliferation rate of subconfluent caMEK-expressing cells when serpinE2 expression was downregulated (Figure 2B). In a previous study, we had shown that expression of activated MEK in intestinal epithelial cells resulted in loss of cell-cell contact growth inhibition and produced colonies or multilayered domes which grew to increased saturation density and formed tumors when transplanted into nude mice . Of note, focus formation assays performed herein revealed that initially, there was little difference in the number of foci obtained between control cells and serpinE2-depleted cells (data not shown). However, serpinE2 silencing markedly reduced the size of foci (Figure 2C) suggesting a reduced capacity of these foci to grow. Indeed, phase-contrast microscopy revealed that the colonies were smaller when serpinE2 was downregulated (Figure 2D). Finally, expression of shSerpinE2 led to a significant decrease in the ability of caMEK-expressing cells to grow under anchorage-independent conditions in soft agarose (Figure 2E).
Cell migration is an important process of tumorigenesis and metastasis. Moreover, we recently reported that intestinal epithelial cells expressing activated MEK1 clearly acquire an increased capacity to migrate as compared to wtMEK-expressing cells . Herein, in an in vitro transwell migration assay, serpinE2 deficiency significantly reduced caMEK-expressing IEC migration to the undersurface of the polycarbonate membrane of Boyden chambers coated with fibronectin or vitronectin (Figure 2F), two extracellular matrix proteins which can interact with serpinE2 [34, 35]. Taken together, these results support a role of serpinE2 in MEK1-induced transformation whereby serpinE2 activates anchorage-independent growth and cell migration.
Expression of serpinE2 in colorectal cancer cells is dependent on MEK/ERK activity
Down-regulation of serpinE2 expression in human colorectal cancer cells inhibits soft agarose colony formation, migration and tumor growth in nude mice
To test the hypothesis that this altered migration and invasion capacity could result from a defect in cell adhesion, adhesion strength to the substrate was examined for control and shSerpinE2(#16)-expressing LoVo cells. Using a trypsin-mediated de-adhesion assay, downregulation of serpinE2 significantly delayed LoVo cell detachment after trypsinization (Figure 6C), suggesting that serpinE2 expression decreases adhesion of colorectal carcinoma cells to the substrate.
SerpinE2 gene expression is up-regulated in human colorectal cancers
We and others have recently reported that expression of a constitutively active mutant of MEK1 in normal intestinal epithelial cells is sufficient to induce growth factor relaxation for DNA synthesis, morphological transformation, growth in soft agar, epithelial to mesenchymal transition and to promote tumor invasion and metastasis [3, 4, 14, 15]. Thus, these data argue that a key role of sustained MEK activity resulting from the constitutive activation of KRAS or BRAF in colorectal carcinoma cells may be to provide signals inducing not only proliferation, but also transformation and tumorigenesis. However, in spite of the obvious role of MEK/ERK kinases in the induction and regulation of intestinal epithelial cell tumorigenesis, little is known as to the molecular mechanisms by which this signaling achieves such functions. In the present study, we show that serpinE2 gene is a MEK1 target in intestinal epithelial cells and that serpinE2 expression and secretion correlate with both MEK1 activity and intestinal epithelial cell transformation. Moreover, targeting of serpinE2 by mRNAi in human colorectal cancer cell lines decreased anchorage independent growth, migration, invasion as well as tumor formation in nude mice. Accordingly, we found an upregulation of serpinE2 mRNA levels in human adenomas and colorectal cancer tissues as compared to corresponding normal tissues.
Oncogenic mutations in KRAS or BRAF occur frequently in colorectal cancer and aberrant signaling through the ERK pathway has been correlated with both initiation  and progression  of CRC. Interestingly, KRAS and BRAF mutations seem to be mutually exclusive [39, 40], suggesting that they may have similar functions. These oncogenes primarily signal through the MEK/ERK pathway [41, 42]. Upon phosphorylation by MEK1/2, ERK1/2 translocate to the nucleus and phosphorylate various transcription factors regulating gene expression . Therefore, in order to define the genetic changes induced by persistent MEK activation, we and others [4, 15] have utilized oligonucleotide microarrays to determine which genes are regulated following the constitutive activation of MEK in normal intestinal epithelial cells. Our results revealed that serpinE2 gene was the gene mostly induced by activated MEK in intestinal epithelial cells. This observed altered level of expression of serpinE2 transcript was also noted in microarray analyses performed by Voisin and colleagues . In the present study, we were able to confirm that RAS-, BRAF- and caMEK-transformed intestinal epithelial cells express and secrete serpinE2. Furthermore, serpinE2 expression was rapidly enhanced (in 1 h) upon induction of oncogenic BRAF in normal intestinal epithelial cells, suggesting an early involvement of this protein in cell transformation. Of note, expression of serpinE2 in human colorectal cancer cell lines was shown to be dependent, at least in part, of endogenous activities of MEK/ERK. Other oncogenic pathways have been previously associated with induction of serpinE2 expression. Indeed, the very oncogenic receptor tyrosine kinase MET was also shown to promote serpinE2 gene expression in a xenograft colon tumor model . Additionally, PTEN deletion has been reported to up-regulate serpinE2 expression in MEF cells  and serpinE2 was shown to be overexpressed in cells transformed by adenovirus type 12 . Taken together, these results indicate that serpinE2 gene expression could be induced by different oncogenic pathways, emphasizing that this protein may be important in tumorigenesis.
Our results also led to the demonstration that serpinE2 contributes to transformation induced by activated MEK1 and to human colorectal carcinoma cell growth and migration. In agreement with the present study, data on serpinE2 expression in human cancer indicate that serpinE2 levels are elevated in pancreatic tumors , breast tumors , liposarcomas  and oral squamous carcinomas . Accordingly, we found a significantly higher level of serpinE2 mRNA when comparing affected tissues from advanced adenomas and carcinomas to adjacent healthy tissues. These results are in agreement with the study of Selzer-Plon et al. who recently reported that serpinE2 mRNA levels increase both at the transition between normal tissue and adenomas with mild/moderate dysplasia and again at the transition between severe dysplasia and colorectal cancer . In addition, no significant difference was observed when comparing serpinE2 mRNA levels in primary cancers classified into different TNM stages. Taken together, the above results suggest that enhanced serpinE2 expression may be implicated in tumor progression in colorectal tissue.
Although there is some evidence in the literature suggesting that serpinE2 may play a role in carcinogenesis, the precise function of this serpin in cancer still remains elusive. Through its ability to reduce proteolysis, this serine protease inhibitor is predicted to impair extracellular matrix degradation and consequently cancer cell invasion and metastasis. However, overexpression of serpinE2 appears to enhance the invasive potential of pancreatic tumors in xenograft models . Recently, using mammary tumor models, it has been reported that serpinE2 stimulates metastatic spread of mammary tumors . In addition, an analysis of 126 breast cancer patients revealed that patients with breast tumors showing elevated serpinE2 levels also had a significantly higher probability of developing lung metastasis . Finally, serpinE2 has recently been shown to promote lymph node metastasis in a testicular cancer model . Thus, increased function of serpinE2 appears to be associated with enhanced migration and metastasis. However, the biological roles of serpinE2 in colorectal carcinoma have never been studied. Herein, the present results show that endogenous expression of serpinE2 in rodent transformed intestinal epithelial cells and human CRC cells is correlated with enhanced cell migration and invasion abilities. The molecular mechanism by which serpinE2 modulates motility remains unknown. It is possible that serpinE2 may enhance signaling cascades mediating motility. In this regard, serpinE2 has recently been reported to stimulate ERK signaling by binding LRP-1  or syndecan-1 . However, preliminary results (data not shown) indicate that the phosphorylated levels of Akt and ERK1/2 were not affected following serpinE2 depletion in colon carcinoma cells. Alternatively, shSerpinE2-expressing cells may have a reduced migratory capacity which could result from a defect in cell adhesion. Indeed, typical cell movement across a two-dimensional substrate can be divided into three concerted steps: membrane protrusion, cell traction, deadhesion and tail retraction. Adhesion at the leading edge and deadhesion at the rear portion of cells are required for protrusion and tail retraction, respectively . As cellular migration and cellular adhesion are intimately related, changes in one could be expected to result in changes in the other. Binding of type-1 plasminogen activator inhibitor (PAI-1), the phylogenetically closest relative of serpinE2, to cell surface uPA promotes inactivation and internalization of adhesion receptors (e.g. urokinase receptor and integrins) and leads to cell detachment from a variety of extracellular matrixes . Recently, serpinE2 has been shown to also induce cell detachment from a variety of extracellular matrix proteins such as vitronectin, fibronectin and type-1 collagen in an uPA/uPAR-dependent manner . Interestingly, serpinE2 has been reported to co-localize with fibronectin  and to interact with vitronectin . Accordingly, we observed herein that the downregulation of serpinE2 significantly delayed colorectal carcinoma cell detachment after trypsinization, suggesting that serpinE2 expression does decrease adhesion and promote detachment of colorectal carcinoma cells. Moreover, we have recently demonstrated that uPA expression levels are enhanced in MEK1-transformed intestinal epithelial cells . Further experiments are hence necessary to clearly identify the molecular mechanisms involved in the deadhesive effects of serpinE2.
Our study identifies the serine protease inhibitor serpinE2 as a novel target of ERK signaling involved in human colorectal tumorigenesis. The strong expression of serpinE2 in human adenomas suggests that this secreted protein might be a potential blood biomarker for early diagnosis of tumors in the colon and the rectum. While further studies are needed to pinpoint the molecular mechanisms by which serpinE2 regulates tumor cell growth and migration, the present study provides novel fundamental insights into the function of serpinE2 in colorectal cancer progression. Hence, serpinE2 may also be a potential therapeutic target for cancer treatment.
The anti-bovine serpinE2 antibody was previously characterized . The antibody recognizing β-actin was obtained from Chemicon International (Billerica, MA). Antibodies recognizing phospho-ERK1/2 (Thr202/Tyr204) #9101 and total ERK were from Cell Signaling Technology (Danvers, MA). The MEK inhibitor U0126 was from Calbiochem-Novabiochem Corp. (San Diego, CA). Human plasma-derived fibronectin and vitronectin were from R&D systems (Minneapolis, MN). MTT was purchased from Invitrogen (Carlsbad, CA). Other materials were obtained from Sigma-Aldrich unless stated otherwise.
The rat intestinal epithelial crypt cell line IEC-6 stably overexpressing pLXIN-wtMEK or -caMEK were previously characterized  and cultured as described . These cell populations were generated after viral infection of wtMEK and caMEK cloned in the retroviral vector pLXIN. The caMEK-expressing cells formed foci at post-confluency, in contrast to pLXIN- and wtMEK-expressing epithelioid cells which formed a monolayer of contact-inhibited cells. Foci from post-confluent caMEK-expressing cells were therefore retrieved by aspiration with a pipette and pooled as one caMEK-expressing cell population. The majority of experiments described herein was performed with this caMEK-expressing cell population and compared to pLXIN and wtMEK-expressing cell populations unless otherwise stated. This strategy was repeated independently three times with other IEC-6 cell cultures and similar results were obtained with all caMEK-expressing cell populations. The IEC6 wtMEK and caMEK were cultured in DMEM containing 5% FCS. The IEC-6-BRAF:ER population was obtained by retroviral infection of IEC-6 cells as previously described  with the plasmid encoding the fusion protein consisting of full-length human BRAFV600E linked to the T1 form of the human estrogen receptor hormone-binding domain and selection of cells resistant to blasticidin S (5 mg/ml). The population displayed strong stimulation of ERK1/2 activity upon β-estradiol or tamoxifen addition as previously reported . IEC6 BRAFV600E cells were cultured in DMEM without phenol red, supplemented with 5% charcoal stripped FCS (Valley Biomedical, Winchester, VA, USA). The transformed cell line Ha-ras IEC-6, previously characterized , was cultured in DMEM containing 5% FCS. The cell line Caco-2/15 was obtained from Dr A. Quaroni (Cornell University, Ithaca, NY) and cultured in DMEM containing 10% FCS, as described previously . The colon carcinoma cell lines HCT116 and HT29 were obtained from ATCC (CCL-247 and HTB-38) and cultured in McCoy's medium (Wisent) containing 10% FCS. The colon adenocarcinoma cell lines Lovo (CCL 229, ATCC) and SW480 (CCL 228, ATCC) were respectively cultured in Ham's F12 medium containing 10% FCS and in DMEM containing 10% FBS. The colon adenocarcinoma cell lines DLD-1 (CCL-21) (kindly obtained from Dr F. Boudreau, Université de Sherbrooke, QC, Canada) and Colo205 (CCL-222, ATCC) were cultured in RPMI medium containing 10% FCS. The colorectal carcinoma cell line T84 (CCL-248) was cultured in DMEM-Ham's F-12 (50:50) containing 10% FBS.
Total RNAs were extracted from newly confluent IEC-6 cells stably expressing wtMEK or caMEK with the RNeasy kit (Qiagen inc., Mississauga, ON, Canada). For microarray analysis, 10 μg of RNA were used for cDNA synthesis, followed by in vitro transcription to generate biotin-labeled cDNAs with a T7 promoter primer having a poly(T) tail for subsequent hybridization. The resulting product was hybridized and processed with the Rat Genome RAE230 2.0 Array GeneChip system (Affymetrix). Three independent experiments were carried out for each condition. Data analysis, normalization, average difference and expression for each feature on the chip were performed using Affymetrix Microarray Suite 5.0 (MAS5) with default parameters (Microarray platform, McGill University and Genome Quebec Innovation Centre). Gene classification according to cellular processes was performed with the Database for Annotation, Visualization and Integrated Discovery (DAVID) http://apps1.niaid.nih.gov/david.
CD1 nu/nu mice were purchased from Charles River Laboratory (Montréal, Canada). All experiments were approved by the animal research committee of the Faculty of Medicine and Health Sciences of the Université de Sherbrooke.
Samples of colon tumors and paired normal colon tissues (at least 10 cm from the tumor) were obtained from patients undergoing surgical resection. Patients did not receive neoadjuvant therapy. Tissues were obtained after patient's written informed consent, according to the protocol approved by the Institutional Human Subject Review Board of the Centre Hospitalier Universitaire de Sherbrooke. Paired tissues were frozen in liquid nitrogen within 15 minutes from resection as recommended by the Canadian Tumor Repository Network http://www.ctrnet.ca and stored in liquid nitrogen until total RNA extraction. Clinical and pathological informations were obtained from medical records. Adenoma samples were endoscopically unresectable and defined as advanced because of their size larger than 1 cm or by the presence of high-grade dysplasia or villous component. Patient's cancers were histologically classified and graded according to overall TNM staging criteria (based on Tumor-, lymph Node- and Metastatic- status).
Reverse transcription PCR
Total RNA was extracted from cultured cell lines or human colorectal adenoma or tumors and their respective adjacent healthy mucosa using the RNeasy mini kit (Qiagen, Canada) using gDNA Eliminator spin columns or an on-column DNAse I digestion step (human samples). Reverse transcription and PCR were performed using AMV-RT (Roche Diagnostics, Canada) and Taq DNA polymerase (Qiagen, Canada) according to the manufacturer's instructions. Real-time PCR analysis (QPCR) was performed using a Light-Cycler apparatus (Roche Diagnostic, Canada) as previously described . Target expression was quantified relatively to β-actin or TBP (rat) or β-2-microglobulin (β2MIC) (human)  expression. Primers rSerpinE2 forward: CCCTACCATGGTGTGAGAGCAT; rSerpinE2 backward: GCCTTTGACGGTTCAAACAT; Primers: mSerpinE2 forward: CCCTACCATGGTGAGAGCAT; mSerpinE2 backward: GCCTTTGATGGCTCAAACAT; hSerpinE2 forward: AATGAAACCAGGGATATGATTGAC; hSerpinE2 backward: TTGCAAGATATGAGAAACATGGAG; β-actin forward: ACCACAGCTGACAGGAAATCG; β-actin backward: AGAGGTCTTTACGCATGTCAACG; TBP forward: TTCAGTTCTGGGAAAATGGTG; TBP backward: GGAGAACAATTCTGGGTTTGA; GAPDH forward: ATGGCCTTCCGTGTTCCTAC; β2MIC backward: TCGCGCTACTCTCTGTTTCTG.
SDS-PAGE and immunoblot analyses were performed as previously described . For culture medium analysis, subconfluent cells cultured in a 100 mm dish were incubated overnight with a fresh 8 mL of serum free medium after which the medium collected and cells harvested in a lysis buffer containing 150 mM NaCl, 1 mM EDTA, 40 mM Tris-HCl, pH 7.6, 1% NP-40 supplemented with protease inhibitors (0.1 mM PMSF, 10 μg/ml leupeptin, 1 μg/ml pepstatin, 10 μg/ml aprotinin). A volume of medium proportional to the total amount of protein in the cell lysate was passed through an Amicon(r) Ultra-4 centrifugal filter unit (10,000 NMWL; Millipore). Laemmli buffer was added to the retentate and boiled for 5 min. Protein concentrations were determined using the bicinchoninic acid (BCA) assay (Pierce) with bovine serum albumin as standard.
Rat IEC6 cells: shRNA oligonucleotides were designed according to Ambion guidelines (technical bulletin no. 506), annealed and cloned into pLenti6-U6 expression vector  between BamHI and XhoI sites. siRNA sequences were AGGAACCATGAATTGGCAT (SerpinE2) or GGCAGTTCAGACAGATTAA (Scrambled) and TTCAAGAGA as loop sequence. Human LoVo and HCT116 cells: To downregulate serpinE2 expression, mission(r) shRNA Bacterial Glycerol Stock were purchased from Sigma-Aldrich (NM_006216). Sequences used were CCGGCCTCGTCAACGCAGTGTATTTCTCGAGAAATACACTGCGTTGACGAGGTTTTTG (shSerpinE2#15), CCGGGAACACAAAGAAACGCACTTTCTCGAGAAAGTGCGTTTCTTTGTGTTCTTTTTG (shSerpinE2#16) and CCGGCGTGATCTTCACCGACAAGATCTCGAGATCTTGTCGGTGAAGATCACGTTTTT (control: TurboGFP(tm) (shTGFP)). All lentiviruses were produced and used for cell infection according to Invitrogen recommendations (ViraPower Lentiviral Expression System, instructions manual). In each experiment involving lentiviruses, OAS1 gene expression was analyzed by Q-PCR analysis. OAS1 (2'5'-oligoadenylate synthetase) is a classic interferon target gene and has been recommended as a key test for interferon induction before attributing a particular response to the gene that is targeted . No induction of OAS1 expression was detected in the experiments involving lentiviruses infection (data not shown).
Cell proliferation assays
All experiments were performed starting with cell populations after at least 14 days post-selection and subsequently plated for growth assay in 6-well plates at a concentration of 100 000 cells/well for IEC-6 and 200 000 cells/well for HCT116 and LoVo. Cell growth was measured during 7-8 days using a Cell particle counter.
Focus formation assays
Parental IEC-6 cells were seeded into 30-mm dishes in triplicate. Cells were grown to confluence and confluent monolayers were adapted over a week-long period to DMEM/5%FBS before seeding of caMEK-expressing cells at high density (5000 cells/well). These cells were then grown by forming foci and maintained in culture for 14-20 days. Thereafter, cells were washed twice with 1× PBS and fixed with methanol for 1 min. Methanol was removed and 1% crystal violet solution was added for 2 min. Excess dye was carefully removed with water and plates were dried at room temperature. Analysis was performed by counting the number and size of the foci using Image J software. Resulting data were analyzed by Student's t test.
Concentrated DMEM-2X without phenol red was prepared from powder (Wisent, Qc Canada) according to manufacturer's instructions, except for using half of the recommended volume of water. The medium was sterilized by 0.22 μm filtration and complemented with 10% (IEC6) or 20% (LoVo and HCT116) FBS. Pre-warmed DMEM-2X was mixed 1:1 with autoclaved 1.4% agarose type VII kept at ≈42°C and 6-well dishes were pre-coated with 1 ml/well. Cells were added to the DMEM-agarose mix at 10000 cells/mL (IEC6) or 5000 cells/mL (LoVo and HCT116) and seeded at 2 mL/well. Plates were allowed to solidify under the hood and then placed at 37°C and 5% CO2. Fresh DMEM without phenol red supplemented with 5% (IEC6) - 10% (LoVo and HCT116) FBS was added on the surface of the agarose every 2-3 days. After 2-3 weeks, colonies were stained by adding 500 μL of PBS containing 0.5 mg/mL MTT on the surface of the agarose and incubated 2 hours at 37°C and 5% CO2. Images were acquired using an AlphaImager camera (Alpha Innotech Corporation) and colonies counted using ImageJ software.
Migration and invasion assays
Cell migration was assessed using Transwell(r)-24 well permeable support (8.0-μm pored polycarbonate membranes (Corning)). The bottom face of membranes was coated or not with 10 μg/μL fibronectin or vitronectin for 1 hour at 37°C and then rinsed with PBS. Thereafter, 3000 cells in 200 μL of serum-free medium were seeded into the upper chamber and culture medium containing 5% FBS was placed into the lower chamber as chemoattractant agent. Cells were allowed to migrate for the next 24 h (IEC-6) or 48 h (LoVo) in the presence of 2 mM hydroxyurea in both chambers to prevent cell proliferation. Non-migrating cells were removed with 2 cotton swabs, while migrating cells were fixed for 2 min with methanol and stained with DAPI for manual counting under the microscope. Invasion assays were conducted using BD Matrigel(tm) Invasion Chamber 24-well plate 8.0 micron according to the manufacturer's instructions. Briefly, plates were thawed at room temperature for 30 min and then Matrigel humidified with HAM'S F12 culture medium for at least 1 hour at 37°C and 5% CO2. Thereafter, 6000 cells in 200 μL of serum-free medium were seeded into the upper chamber and culture medium containing 5% FBS was placed into the lower chamber as chemoattractant agent. Cells were allowed to migrate for the next 48 h in the presence of 2 mM hydroxyurea in both chambers to prevent cell proliferation . Cells were then processed as described above for migration assays.
Xenografts into nude mice
A total of 1 × 106 cells suspended in 0.1 ml DMEM were injected into the dorsal subcutaneous (s.c.) tissue of 5-week-old female nude mice CD1 nu/nu (Charles River, Canada). Both control and experimental cell lines were contralaterally injected into each individual animal. Tumor volume was determined by external measurement according to published methods (d2 x D)/2 .
Subconfluent cells were rinsed twice with PBS before addition of 500 μL of 0.25% trypsin/0.1 mM EDTA (Wisent, Qc, Canada) per well of a 6-well dish. Plates were rocked at 100 RPM at room temperature until cells were completely detached.
Data Presentation and Statistical Analysis
Densitometric analyses were performed using Image J software and were carried out in RT-PCR analyses shown in Figure 1. Results shown in the graphs were analyzed by the Student's t test. Differences were considered significantly different at p < 0.05, unless otherwise stated. Results shown are the mean of at least three independent experiments.
We thank Anne Vézina and Gérald Bernatchez for technical assistance. The biobank of colorectal cancer specimens was supported by a Team grant on digestive epithelium from the Canadian Institutes of Health Research. This research was supported by a grant from the Canadian Institutes of Health Research Grant to Nathalie Rivard (MT-14405). Sébastien Bergeron is a recipient of a post-doctoral fellowship from the Canadian Association of Gastroenterology/CIHR/CCFC. Étienne Lemieux is student scholar from the Fonds de la Recherche en Santé du Québec (FRSQ). Nathalie Rivard, Marie-Josée Boucher and Julie C Carrier are members of the FRSQ-Funded Centre de Recherche Clinique Étienne Le-Bel. Marie-Josée Boucher and Julie C Carrier are recipient of a scholar from FRSQ. Nathalie Rivard is a recipient of a Canadian Research Chair in Signaling and Digestive Physiopathology.
- Nishimura T: Total number of genome alterations in sporadic gastrointestinal cancer inferred from pooled analyses in the literature. Tumour Biol. 2008, 29: 343-350. 10.1159/000176044View ArticlePubMed
- Reddy KB, Nabha SM, Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 2003, 22: 395-403. 10.1023/A:1023781114568View ArticlePubMed
- Boucher MJ, Jean D, Vezina A, Rivard N: Dual role of MEK/ERK signaling in senescence and transformation of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2004, 286: G736-G746. 10.1152/ajpgi.00453.2003View ArticlePubMed
- Komatsu K, Buchanan FG, Katkuri S, Morrow JD, Inoue H, Otaka M: Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology. 2005, 129: 577-590.View ArticlePubMed
- Eggstein S, Franke M, Kutschka I, Manthey G, von Specht BU, Ruf G: Expression and activity of mitogen activated protein kinases in human colorectal carcinoma. Gut. 1999, 44: 834-838. 10.1136/gut.44.6.834PubMed CentralView ArticlePubMed
- Lee SH, Lee JW, Soung YH, Kim SY, Nam SW, Park WS: Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. APMIS. 2004, 112: 233-238. 10.1111/j.1600-0463.2004.apm11204-0502.xView ArticlePubMed
- Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999, 18: 813-822. 10.1038/sj.onc.1202367View ArticlePubMed
- Kuno Y, Kondo K, Iwata H, Senga T, Akiyama S, Ito K: Tumor-specific activation of mitogen-activated protein kinase in human colorectal and gastric carcinoma tissues. Jpn J Cancer Res. 1998, 89: 903-909.View ArticlePubMed
- Licato LL, Brenner DA: Analysis of signaling protein kinases in human colon or colorectal carcinomas. Dig Dis Sci. 1998, 43: 1454-1464. 10.1023/A:1018894227169View ArticlePubMed
- Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007, 26: 3291-3310. 10.1038/sj.onc.1210422View ArticlePubMed
- Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008, 26: 2139-2146. 10.1200/JCO.2007.14.4956PubMed CentralView ArticlePubMed
- Wang JY, Wilcoxen KM, Nomoto K, Wu S: Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem. 2007, 7: 1364-1378. 10.2174/156802607781696837View ArticlePubMed
- Licato LL, Keku TO, Wurzelmann JI, Murray SC, Woosley JT, Sandler RS: In vivo activation of mitogen-activated protein kinases in rat intestinal neoplasia. Gastroenterology. 1997, 113: 1589-1598. 10.1053/gast.1997.v113.pm9352861View ArticlePubMed
- Lemieux E, Bergeron S, Durand V, Asselin C, Saucier C, Rivard N: Constitutively active MEK1 is sufficient to induce epithelial-to-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. Int J Cancer. 2009, 125: 1575-1586. 10.1002/ijc.24485View ArticlePubMed
- Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, Saba-El-Leil MK: Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer. 2008, 8: 337- 10.1186/1471-2407-8-337PubMed CentralView ArticlePubMed
- Fang JY, Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005, 6: 322-327. 10.1016/S1470-2045(05)70168-6View ArticlePubMed
- Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG: The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem. 2001, 276: 33293-33296. 10.1074/jbc.R100016200View ArticlePubMed
- Vassalli JD, Huarte J, Bosco D, Sappino AP, Sappino N, Velardi A: Protease-nexin I as an androgen-dependent secretory product of the murine seminal vesicle. EMBO J. 1993, 12: 1871-1878.PubMed CentralPubMed
- Chen LM, Zhang X, Chai KX: Regulation of prostasin expression and function in the prostate. Prostate. 2004, 59: 1-12. 10.1002/pros.10346View ArticlePubMed
- Myerburg MM, McKenna EE, Luke CJ, Frizzell RA, Kleyman TR, Pilewski JM: Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008, 294: L932-L941. 10.1152/ajplung.00437.2007PubMed CentralView ArticlePubMed
- Gurwitz D, Simon MM, Fruth U, Cunningham DD: Protease nexin-1 complexes and inhibits T cell serine proteinase-1. Biochem Biophys Res Commun. 1989, 161: 300-304. 10.1016/0006-291X(89)91596-9View ArticlePubMed
- Baker JB, Low DA, Simmer RL, Cunningham DD: Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell. 1980, 21: 37-45. 10.1016/0092-8674(80)90112-9View ArticlePubMed
- Scott RW, Bergman BL, Bajpai A, Hersh RT, Rodriguez H, Jones BN: Protease nexin. Properties and a modified purification procedure. J Biol Chem. 1985, 260: 7029-7034.PubMed
- Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998, 4: 923-928. 10.1038/nm0898-923View ArticlePubMed
- Liu G, Shuman MA, Cohen RL: Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer. 1995, 60: 501-506. 10.1002/ijc.2910600413View ArticlePubMed
- Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM: Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell. 2008, 14: 324-334. 10.1016/j.ccr.2008.08.012PubMed CentralView ArticlePubMed
- Buchholz M, Biebl A, Neesse A, Wagner M, Iwamura T, Leder G: SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res. 2003, 63: 4945-4951.PubMed
- Candia BJ, Hines WC, Heaphy CM, Griffith JK, Orlando RA: Protease nexin-1 expression is altered in human breast cancer. Cancer Cell Int. 2006, 6: 16- 10.1186/1475-2867-6-16PubMed CentralView ArticlePubMed
- Yang S, Dong Q, Yao M, Shi M, Ye J, Zhao L: Establishment of an experimental human lung adenocarcinoma cell line SPC-A-1BM with high bone metastases potency by (99m)Tc-MDP bone scintigraphy. Nucl Med Biol. 2009, 36: 313-321. 10.1016/j.nucmedbio.2008.12.007View ArticlePubMed
- Gao S, Krogdahl A, Sorensen JA, Kousted TM, Dabelsteen E, Andreasen PA: Overexpression of protease nexin-1 mRNA and protein in oral squamous cell carcinomas. Oral Oncol. 2008, 44: 309-313. 10.1016/j.oraloncology.2007.02.009View ArticlePubMed
- Thelin-Jarnum S, Lassen C, Panagopoulos I, Mandahl N, Aman P: Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas. Int J Cancer. 1999, 83: 30-33. 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4View ArticlePubMed
- Selzer-Plon J, Bornholdt J, Friis S, Bisgaard HC, Lothe IM, Tveit KM: Expression of prostasin and its inhibitors during colorectal cancer carcinogenesis. BMC Cancer. 2009, 9: 201- 10.1186/1471-2407-9-201PubMed CentralView ArticlePubMed
- Low DA, Baker JB, Koonce WC, Cunningham DD: Released protease-nexin regulates cellular binding, internalization, and degradation of serine proteases. Proc Natl Acad Sci USA. 1981, 78: 2340-2344. 10.1073/pnas.78.4.2340PubMed CentralView ArticlePubMed
- Farrell DH, Wagner SL, Yuan RH, Cunningham DD: Localization of protease nexin-1 on the fibroblast extracellular matrix. J Cell Physiol. 1988, 134: 179-188. 10.1002/jcp.1041340203View ArticlePubMed
- Rovelli G, Stone SR, Preissner KT, Monard D: Specific interaction of vitronectin with the cell-secreted protease inhibitor glia-derived nexin and its thrombin complex. Eur J Biochem. 1990, 192: 797-803. 10.1111/j.1432-1033.1990.tb19293.xView ArticlePubMed
- Wang Z, Li Y, Liu ET, Yu Q: Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. Biochem Biophys Res Commun. 2004, 322: 609-613. 10.1016/j.bbrc.2004.07.166View ArticlePubMed
- Trainer DL, Kline T, McCabe FL, Faucette LF, Feild J, Chaikin M: Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer. 1988, 41: 287-296. 10.1002/ijc.2910410221View ArticlePubMed
- Calcagno SR, Li S, Colon M, Kreinest PA, Thompson EA, Fields AP: Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer. 2008, 122: 2462-2470. 10.1002/ijc.23383PubMed CentralView ArticlePubMed
- Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002, 62: 6451-6455.PubMed
- Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B: BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer. 2006, 5: 2- 10.1186/1476-4598-5-2View ArticlePubMed
- Niault T, Baccarini M: Targets of Raf in tumorigenesis. Carcinogenesis. 2010,
- Wong KK: Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov. 2009, 4: 28-35. 10.2174/157489209787002461View ArticlePubMed
- Treisman R: Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol. 1996, 8: 205-215. 10.1016/S0955-0674(96)80067-6View ArticlePubMed
- van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y: Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia. 2009, 11: 355-364.PubMed CentralView ArticlePubMed
- Li G, Hu Y, Huo Y, Liu M, Freeman D, Gao J: PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin. J Biol Chem. 2006, 281: 10663-10668. 10.1074/jbc.M512509200View ArticlePubMed
- Guan H, Smirnov DA, Ricciardi RP: Identification of genes associated with adenovirus 12 tumorigenesis by microarray. Virology. 2003, 309: 114-124. 10.1016/S0042-6822(02)00135-6View ArticlePubMed
- Fayard B, Bianchi F, Dey J, Moreno E, Djaffer S, Hynes NE: The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Res. 2009, 69: 5690-5698. 10.1158/0008-5472.CAN-08-4573View ArticlePubMed
- Nagahara A, Nakayama M, Oka D, Tsuchiya M, Kawashima A, Mukai M: SERPINE2 is a possible candidate promotor for lymph node metastasis in testicular cancer. Biochem Biophys Res Commun. 2010, 391: 1641-1646. 10.1016/j.bbrc.2009.12.105View ArticlePubMed
- Li X, Herz J, Monard D: Activation of ERK signaling upon alternative protease nexin-1 internalization mediated by syndecan-1. J Cell Biochem. 2006, 99: 936-951. 10.1002/jcb.20881View ArticlePubMed
- Le Clainche C, Carlier MF: Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol Rev. 2008, 88: 489-513. 10.1152/physrev.00021.2007View ArticlePubMed
- Czekay RP, Loskutoff DJ: Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood). 2004, 229: 1090-1096.
- Czekay RP, Loskutoff DJ: Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. J Cell Physiol. 2009, 220: 655-663. 10.1002/jcp.21806PubMed CentralView ArticlePubMed
- Bedard J, Brule S, Price CA, Silversides DW, Lussier JG: Serine protease inhibitor-E2 (SERPINE2) is differentially expressed in granulosa cells of dominant follicle in cattle. Mol Reprod Dev. 2003, 64: 152-165. 10.1002/mrd.10239View ArticlePubMed
- Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY: Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene. 2007, 26: 1954-1958. 10.1038/sj.onc.1209994PubMed CentralView ArticlePubMed
- Boudreau F, Zannoni S, Pelletier N, Bardati T, Yu SJ, Asselin C: Negative regulation of glucocorticoid-dependent induction of c-fos by ras in intestinal epithelial cells. Mol Cell Biochem. 1999, 195: 99-111. 10.1023/A:1006987313013View ArticlePubMed
- Deschenes C, Vezina A, Beaulieu JF, Rivard N: Role of p27(Kip1) in human intestinal cell differentiation. Gastroenterology. 2001, 120: 423-438. 10.1053/gast.2001.21199View ArticlePubMed
- Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF: Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol. 2006, 290: G1067-G1074. 10.1152/ajpgi.00234.2005View ArticlePubMed
- Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R: Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet. 2003, 34: 263-264. 10.1038/ng1173View ArticlePubMed
- Calzado MA, Macho A, Lucena C, Munoz E: Hydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoter. Clin Exp Immunol. 2000, 120: 317-323. 10.1046/j.1365-2249.2000.01203.xPubMed CentralView ArticlePubMed
- Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J: Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem. 1995, 270: 22044-22049. 10.1074/jbc.270.37.22044View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.